SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is surging above $71,000, igniting community excitement and signaling a potential end to recent downtrends as many anticipate a new bull phase and the liquidation of short positions. The rally is supported by ongoing conversations around proposed crypto legislation, with prominent figures criticizing banks for hindering market progress, and some investors increasingly viewing Bitcoin as a resilient asset amidst global uncertainty.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amidst surging crude oil prices driven by escalating Middle East tensions and threats to the Strait of Hormuz, sparking intense community debate as the stock experiences a sharp sell-off. Investors are questioning potential market manipulation or dilution, while others anticipate a significant rebound due to its low float and high short interest.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending as a highly leveraged bet on Bitcoin's price movements, with community sentiment sharply divided. Bulls are actively discussing the potential for a significant short squeeze as MSTR continues its strategy of acquiring more BTC, while bears express concern over ongoing share dilution and the company's valuation.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is gaining significant traction following a definitive commercial agreement and strategic investment from TELUS, reinforcing its commercial validation and financial runway. The community is overwhelmingly bullish on the company's strong earnings, projecting substantial revenue growth and accelerating satellite deployment, particularly as it displays remarkable strength amidst a challenging market.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to its announced strategic partnership with Starwood Capital to develop AI/HPC data centers, a significant pivot from pure Bitcoin mining that is sparking fervent debate among investors. Despite a substantial Q4 net loss driven by Bitcoin write-downs, the community is weighing this diversification as a potential long-term value driver against concerns about execution and market timing.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending sharply higher after strong Q4 earnings highlighted immense growth in USDC circulation and profitability, triggering a significant short squeeze. Community discussion points to its crucial role in stablecoin adoption and the emerging AI agent commerce landscape as key drivers.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending as its upcoming earnings report sparks fervent debate among investors, who are torn between expectations of a strong beat driven by platform growth and crypto activity, and frustration over perceived market manipulation and an unresponsive CEO that has kept the stock at seemingly undervalued levels.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after its earnings call, where the CEO's comparison of the company's long-term potential to Tesla and Nvidia, coupled with 700% year-over-year revenue growth and global expansion, has ignited community debate, with some viewing recent price volatility as "sell the news" while others focus on the transformative vision.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid high anticipation for its upcoming earnings, as the community fiercely debates its valuation and strategic position in the evolving Agentic AI landscape. Investors are polarized between those highlighting its strong balance sheet, institutional ownership, and role as an AI orchestration platform, and those concerned about competition and recent price weakness, fueling speculation of a potential short squeeze.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF ($EWY) is seeing a sharp market pullback, triggered by rising Middle East tensions and surging energy prices, leading to a community debate. While some perceive a crowded trade correction, many argue the panic is overblown, citing South Korea's diversified energy resilience and the continued AI-driven demand for its dominant semiconductor giants.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vivtex will license select drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion.</li><li>The partnership looks to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally.</li><li>This partnership comes a day after Novo announced plans to cut U.S. prices for Ozempic and Wegovy by up to 50% from 2027.</li></ul>Novo Nordisk (NVO) announced on Wednesday that it has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes, and related conditions.Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion in upfront payments, research funding, milestones, and tiered royalties on future sales.“Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection,” said Thomas von Erlach, CEO and co-founder of Vivtex.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 1.8% at the time of writing.<h2 class="st-heading-2">Focus On Oral Delivery</h2>The partnership combines Novo’s expertise in peptide and protein therapies with Vivtex’s gastrointestinal screening tools, drug-delivery technologies, and AI-based platform aimed at improving drug absorption.The collaboration aims to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally. Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of any resulting products, it said.Oral obesity pills are seen as a key focus area in the obesity market, eliminating the need for injections and giving patients greater flexibility.This comes a day after Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cut-ozempic-wegovy-prices-by-50/cZRvxJeR4C2">announced</a> plans to cut U.S. prices for Ozempic and Wegovy by up to 50% starting in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user sees the stock as a “short-term buy” option.<stembedurl>https://stocktwits.com/buddyopalosam/message/645859049</stembedurl>Another user said the stock was ‘undervalued.’<stembedurl>https://stocktwits.com/Matt_Y_/message/645842315</stembedurl>Year-to-date, the stock is down around 27%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Equity

<ul class="summary-bullets"><li>Geron posted RYTELO net product sales of $48 million in the fourth quarter, and the number of ordering accounts increased to roughly 1,300.</li><li>In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.</li><li>For 2026, Geron projects RYTELO revenue between $220 million and $240 million.</li></ul>Geron Corp. (GERN) reported fourth-quarter and full-year 2025 results on Wednesday, highlighting rising sales of its blood cancer therapy RYTELO as the company sharpens its focus on expanding adoption in lower-risk myelodysplastic syndromes (LR-MDS).Total revenue reached $48 million in the fourth quarter, with a loss per share (EPS) of $0.05. Both the metrics&nbsp;came&nbsp;in below the analysts’ consensus estimates of $50.88 million and a loss of $0.04, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">RYTELO Sales And Demand Climb</h2>However, Geron posted RYTELO net product sales of $48 million for Q4 and $183.6 million for the full year. Demand rose 9% in the fourth quarter compared with the prior quarter, while the number of ordering accounts increased by 150 to roughly 1,300.The company said it is supporting more than 10 investigator-sponsored and real-world studies examining RYTELO’s mechanism, potential combinations, and earlier-line use. Initial findings from those efforts are anticipated in the second half of 2026.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GERN">Geron's stock</a> traded over 10% lower in Wednesday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Expenses And Outlook&nbsp;</h2>Operating costs for 2025 were $254.7 million. Research and development spending declined, reflecting reduced clinical trial activity after the FDA’s RYTELO approval in 2024. Selling, general, and administrative costs increased due to expanded commercial efforts. In December, Geron initiated a workforce reduction affecting about one-third of employees, resulting in $17 million in restructuring charges.For 2026, Geron projects RYTELO revenue of $220 million to $240 million, with operating expenses of $230 million to $240 million.GERN stock declined by over 17% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rbbn-stock-gains-pre-market-today-what-is-behind-the-rally/cZRyd8HRIGE">RBBN Stock Gains Over 8% Pre-Market Today – What’s Behind The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did GERN Stock Tumble 10% Pre-Market Today? 

Total revenue reached $48 million for the fourth quarter, with a loss per share of $0.05, with both metrics coming in below street estimates. 

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

<ul class="summary-bullets"><li>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements when compared to placebo on key secondary endpoints.</li><li>Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, compared to 2% in the placebo group.</li><li>The company’s Chief Scientific Officer, Martin Holst Lange, added that Novo Nordisk is looking forward to reporting data from a global trial with UBT251 next year.</li></ul>Novo Nordisk AS (NVO) on Tuesday announced that its phase 2 clinical trial of a new obesity drug in China has shown successful results.Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.However,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> declined nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">UBT251 Trial Results Show Significant Improvements</h2>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements compared with placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids.The trial investigated the safety and efficacy of UBT251 at doses of 2 mg, 4 mg, and 6 mg.Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, or about 17.5 kg, compared to 2% or 1.6kg in the placebo group after 24 weeks of treatment.“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange.Lange added that the company is looking forward to reporting data from a global trial with UBT251 next year.<h2 class="st-heading-2">Why Is NVO Stock Declining Pre-Market?</h2>Novo Nordisk shares continued to decline in Tuesday’s pre-market session. This is after a fall of more than 16% on Monday, following the company's announcement that CagriSema demonstrated 23% weight loss in people with obesity in the Redefine 4 trial,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC">failing to meet</a> its primary endpoint.According to TheFly, analysts at JPMorgan downgraded Novo Nordisk to ‘Neutral’ from ‘Overweight’, calling the CagriSema results “disappointing.”The firm also further reduced its CagriSema forecasts by up to 63% through 2030, expecting a more challenging uptake for the product given its "inferiority" to Eli Lilly and Co.’s (LLY) Zepbound.Analysts at Kepler Cheuvreux downgraded NVO to ‘Hold’ from ‘Buy’ and stated that the company’s Redefine 4 study was a “major negative surprise.”Nordea analysts also downgraded Novo Nordisk to ‘Hold’ from ‘Buy’, with the firm citing a lack of near-term catalysts following Monday’s obesity study results.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status/cZRtw5dR4yV">Is Microsoft Down? MSFT 365 Error Reports Spike On Downdetector, Company Says It Is Investigating The Issue</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

<ul class="summary-bullets"><li>Merck said it will reorganize its human health segment into two separate units.</li><li>Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International.&nbsp;</li><li>The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard.</li></ul>Merck &amp; Co. Inc. (MRK) announced on Monday that it is overhauling the leadership structure of its flagship pharmaceutical division as the company prepares for looming revenue headwinds tied to its top-selling cancer therapy.&nbsp;The Rahway, New Jersey-based drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.<h2 class="st-heading-2">Preparing For Keytruda Patent Expiration</h2>One of the units will concentrate on&nbsp;Oncology business, while the other will house the specialty, pharma, and infectious diseases business.&nbsp;According to the Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65">report</a>, the restructuring comes as Merck braces for the loss of U.S. market exclusivity for Keytruda in 2028, a development expected to invite lower-priced competition and dent sales.&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merck stock</a> traded over 1% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory, with message volume shifted to ‘low’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">New Leadership To Drive Growth&nbsp;</h2>To guide the oncology-focused arm, Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International. The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard, who will join Merck effective March 2.&nbsp;<h2 class="st-heading-2">Building Beyond Keytruda&nbsp;</h2>According to the report, Merck has spent heavily on acquisitions in recent years to bolster its pipeline and cushion the anticipated slowdown in Keytruda sales.“As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma &amp; Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating long‑term value for our stakeholders.”-Robert M. Davis, Chairman and CEO, Merck&nbsp;Merck said it currently has roughly 80 Phase 3 trials underway and anticipates launching more than 20 new growth drivers in the coming years, most of which it believes could achieve blockbuster status.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-tomz-stock-soaring-pre-market-today-a-key-uk-approval-may-be-the-catalyst/cZRt8hkR4y4">Why Is TOMZ Stock Soaring Pre-Market Today? A Key UK Approval May Be The Catalyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Splits Oncology, Specialty Operations To Brace For Keytruda Patent Loss – Overhauls Leadership To Drive Growth 

The drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

<ul class="summary-bullets"><li>The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.</li><li>People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.</li><li>When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.</li></ul>Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> trended in the ‘extremely bearish’ territory at the time of writing.<h2 class="st-heading-2">CagriSema Fails To Match Tirzepatide In Effectiveness</h2>Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.<h2 class="st-heading-2">Who Is CagriSema Aimed At?</h2>CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-replicate-most-tariffs-after-supreme-court-ruling-goldman-sachs/cZRNfSqR4xV">Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

<ul class="summary-bullets"><li>The Danish pharmaceutical giant is expanding operations at its Athlone site.</li><li>CEO Mike Doustdar did not disclose how much the company plans to spend.</li><li>&nbsp;Doustdar said more than 240,000 people in the U.S. have already begun taking Wegovy in the form of pills.</li></ul>Novo Nordisk (NVO) is reportedly planning to ramp up its manufacturing footprint in Ireland as it prepares to increase production of its blockbuster Wegovy weight-loss pill for patients outside the U.S.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-12/novo-set-to-make-wegovy-pill-in-ireland-for-markets-outside-us?srnd=homepage-americas">report</a>, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.Doustdar did not disclose how much the company plans to spend but emphasized that the expansion signals confidence in the product’s global prospects. The Danish pharmaceutical giant is expanding operations at its site in Athlone, a move that underscores its renewed push in the highly competitive obesity drug market.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> inched 0.6% higher in Thursday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘normal’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Strong Early Demand</h2>The report cited that Wegovy’s pill form debuted in early January and quickly gained traction. Doustdar said more than 240,000 people in the U.S. have already begun taking the medication, calling it one of the most successful rollouts in the industry.Novo manufactures the U.S. supply domestically, while the Irish site will focus on serving markets beyond the U.S. On Wednesday, Doustdar said the company is planning to offer Wegovy injectables in vial form, similar to what competitor Eli Lilly and Company (LLY) has done.The latest push in Ireland comes as Novo works to regain momentum in the weight-management segment it once led. The company had previously warned about several challenges in 2026, including intense competition, lower selling prices, and the loss of patent protection for the main ingredient in its drugs, Wegovy and Ozempic, in some countries outside the U.S.NVO stock has declined by over 40% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-rises-premarket-ahead-of-q4-earnings-r2-suv-reveal-nears-benchmark-sees-upside/cZRThmWR4AC">Rivian Stock Rises Premarket Ahead Of Q4 Earnings As R2 SUV Reveal Nears — Benchmark Sees Over 20% Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report 

According to a Bloomberg report, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.

<ul class="summary-bullets"><li>The FDA stated that the totality of the claims made by Novo in the ad misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.</li><li>The agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments.</li><li>The FDA has sought a reply from Novo within 15 working days from the date of receipt.</li></ul>A television advertisement by Novo Nordisk A/S (NVO) for its obesity pill Wegovy has been flagged as “misleading” by the U.S. Food and Drug Administration (FDA).According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. It added that this violates the distribution provisions of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 8% in Monday’s opening trade, but pared some of the gains to hover nearly 4% higher at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” said Liz Skrbkova, Novo’s head of U.S. media and stakeholder relations, according to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/09/fda-novo-nordisk-wegovy-tv-ad.html">report</a>.<h2 class="st-heading-2">What Is The FDA Objecting To?</h2>The FDA stated that the totality of the claims made by Novo in the TV advertisement misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.“Specifically, these claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss,” the FDA stated in its letter.In particular, the agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments, even though this has not yet been demonstrated.Beyond this, the FDA stated that the advertisement implies additional benefits such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the pill as a solution to broader life problems rather than just a specific physical condition.The agency has sought a reply from Novo within 15 working days of receipt.<h2 class="st-heading-2">Novo’s Legal Battle With Hims &amp; Hers</h2>The FDA letter comes amid Novo’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">legal battle</a> with Hims &amp; Hers Health Inc. (HIMS). The Wegovy-maker sued Hims &amp; Hers, calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process,” the company said.Last week, the FDA warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 4% year-to-date and 43% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

<ul class="summary-bullets"><li>Novo also stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.</li><li>Last week, the U.S. Food and Drug Administration warned of a crackdown last week on GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs.</li><li>Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.</li></ul>Novo Nordisk A/S (NVO) on Monday stated that it has filed a lawsuit against Hims &amp; Hers Health Inc. (HIMS), calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 5% in Monday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were down more than 19% at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.<h2 class="st-heading-2">Novo Accuses HIMS Of Duping Consumers</h2>Novo stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process – that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective,” said Novo Nordisk’s senior vice president, Group General Counsel, Global Legal, IP and Security, John F. Kuckelman.The company also announced a share repurchase program on Monday of up to DKK 15 billion ($2.4 billion to be executed during a 12-month period beginning Feb. 4, 2026.<h2 class="st-heading-2">FDA Warns Of Crackdown On Compounded GLP-1 Drugs&nbsp;</h2>Last week, the U.S. Food and Drug Administration (FDA) warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<h2 class="st-heading-2">Analysts Warn Of Sales Hit</h2>The FDA crackdown has resulted in sharp price target cuts from analysts, according to TheFly.Analysts at Citi warned that Hims &amp; Hers’ launch of the compounded pill version of Wegovy is “risky and aggressive,” and that it brings more legal risk to the company.The firm trimmed its price target for Hims &amp; Hers to $16.5 from $30, while maintaining a ‘Sell’ rating. Citi analysts stated that the new price target factors in a 25% bear case probability of Hims &amp; Hers losing all weight loss drug sales, a 60% base case probability of the company losing half of the sales, and a 15% bull case probability of limited GLP-1 downside from the legal challenges.Analysts at BofA also lowered their price target for the HIMS stock to $21 from $26, while keeping an ‘Underperform’ rating. The firm noted that the FDA did not make a distinction between oral and injectable products in its crackdown warning.This leads BofA analysts to believe that the FDA’s crackdown could extend beyond APIs for oral GLP-1 treatment and include APIs for injectable semaglutide as well. The firm believes this adds a new risk to Hims' injectable GLP-1 franchise.<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers</a> trended in the ‘extremely bullish’ territory at the time of writing.One user pointed out that the company’s legal battle with Novo hasn’t even started yet.<stembedurl>https://stocktwits.com/weqwewqeq1111/message/644437840</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 29%.$1 = DKK 6.30Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pgy-stock-rising-today-ahead-of-ai-lenders-q4-earnings/cZbHxXpR48v">PGY Stock Pops Pre-Earnings: Wall Street Bets On Pagaya’s AI-Powered Lending Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

PPH
VanEck Pharmaceutical ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PPH News

PPHVanEck Pharmaceutical ETF